^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    imalumab (BAX069)

    i
    Other names: BAX069, BAX69
    Associations

    News

    Trials
    Company:
    Takeda
    Drug class:
    MIF inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. (PubMed, Mol Cancer Ther)
    In vivo, ON203 mAb demonstrated superior efficacy over imalumab in both prophylactic and established prostate cancer (PC3) mouse xenograft models. In summary, our data highlight the potential of the second-generation anti-oxMIF mAb ON203 as a promising immunotherapy for patients with solid tumors, warranting clinical evaluation.
    Preclinical • Journal • IO biomarker
    |
    MIF (Macrophage Migration Inhibitory Factor)
    |
    ON203 • imalumab (BAX069)